06:06:57 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



GW Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference

2014-11-26 02:00 ET - News Release

LONDON, Nov. 26, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, 3 December, 2014 at 12:30 p.m. EST time. The conference is being held at the New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:  
   
GW Pharmaceuticals plc(Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
   
FTI Consulting (Media Enquiries)  
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
   
Trout Group, LLC (U.S. investor relations)  
Todd James / Chad Rubin 646 378 2900

© 2024 Canjex Publishing Ltd. All rights reserved.